Iovance Biotherapeutics Inc (NASDAQ:IOVA) was the target of unusually large options trading on Monday. Traders acquired 7,578 call options on the stock. This represents an increase of 210% compared to the average daily volume of 2,444 call options.

Shares of IOVA stock traded up $0.49 during trading hours on Wednesday, hitting $36.21. 48,386 shares of the company’s stock were exchanged, compared to its average volume of 1,760,943. The company has a market capitalization of $5.23 billion, a PE ratio of -18.91 and a beta of 1.03. Iovance Biotherapeutics has a 12-month low of $17.67 and a 12-month high of $41.49. The business’s 50 day simple moving average is $30.07 and its 200-day simple moving average is $31.25.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.05. On average, sell-side analysts anticipate that Iovance Biotherapeutics will post -1.94 EPS for the current fiscal year.

Several research analysts have weighed in on IOVA shares. Zacks Investment Research downgraded Iovance Biotherapeutics from a “buy” rating to a “hold” rating and set a $33.00 price target for the company. in a research note on Tuesday, August 4th. BidaskClub upgraded Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, September 1st. Stifel Nicolaus increased their price target on Iovance Biotherapeutics from $48.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Chardan Capital increased their price target on Iovance Biotherapeutics from $44.00 to $53.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Oppenheimer restated a “buy” rating and set a $43.00 price target on shares of Iovance Biotherapeutics in a report on Friday, August 7th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $46.73.

Several hedge funds and other institutional investors have recently modified their holdings of IOVA. Envestnet Asset Management Inc. acquired a new stake in shares of Iovance Biotherapeutics in the first quarter worth approximately $336,000. Aperio Group LLC increased its stake in Iovance Biotherapeutics by 530.4% in the 1st quarter. Aperio Group LLC now owns 16,492 shares of the biotechnology company’s stock valued at $494,000 after buying an additional 13,876 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in Iovance Biotherapeutics by 19.7% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 49,072 shares of the biotechnology company’s stock valued at $1,469,000 after buying an additional 8,090 shares during the last quarter. Arizona State Retirement System acquired a new stake in Iovance Biotherapeutics in the 1st quarter valued at $754,000. Finally, New York State Common Retirement Fund increased its stake in Iovance Biotherapeutics by 8.0% in the 1st quarter. New York State Common Retirement Fund now owns 451,141 shares of the biotechnology company’s stock valued at $13,505,000 after buying an additional 33,402 shares during the last quarter. 95.15% of the stock is currently owned by institutional investors.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Read More: What are catch-up contributions?

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.